Because the released anti-PDL1 antibody effectively blocks the PD1/PDL1 pathway while PexD efficiently stimulates the antitumor immune response by inducing tumor immunogenic cell death, entering the systemic circulation through damaged blood vessels, and attaching to circulating tumor cells, the combined use of anti-PDL1 antibodies and PexD triggers strong T cell immunogenic responses, which ultimately initiate the host’s immunogenic response by inhibiting both metastatic potential postsurgery as well as local tumor recurrence [113]. The gene discussed is CD274; the disease is neoplasm.